TRCT
ALNA

Tower Research Capital (TRC)’s Allena Pharmaceuticals ALNA Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALNA Stock Details ALNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,645
Closed -$2K – 6976
2022
Q1 		$2K Buy
+10,645
New +$4.41K ﹤0.01% 5718
2021
Q4 		– Sell
-5,189
Closed -$5K – 6938
2021
Q3 		$5K Buy
5,189
+1,254
+32% +$1.23K ﹤0.01% 4928
2021
Q2 		$5K Buy
3,935
+3,813
+3,125% +$4.62K ﹤0.01% 4772
2021
Q1 		$0 Sell
122
-13,623
-99% -$22.7K ﹤0.01% 5920
2020
Q4 		$18K Sell
13,745
-4,377
-24% -$6.1K ﹤0.01% 3955
2020
Q3 		$27K Buy
+18,122
New +$25.5K ﹤0.01% 3768
2020
Q1 		– Sell
-467
Closed -$1K – 4231
2019
Q4 		$1K Buy
+467
New +$1.53K ﹤0.01% 3376
2019
Q3 		– Sell
-839
Closed -$3K – 4686
2019
Q2 		$3K Buy
+839
New +$4.58K ﹤0.01% 3198
2019
Q1 		– Sell
-1,049
Closed -$6K – 4503
2018
Q4 		$6K Sell
1,049
-723
-41% -$6.23K ﹤0.01% 2843
2018
Q3 		$19K Buy
+1,772
New +$19.5K ﹤0.01% 2401
2018
Q1 		– Sell
-2,232
Closed -$22K – 4044
2017
Q4 		$22K Buy
+2,232
New +$27.5K ﹤0.01% 2002

Other funds holding ALNA

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Tower Research Capital (TRC)'s ALNA Position: Q2 2022 in Review

Tower Research Capital (TRC) sold out of Allena Pharmaceuticals (ALNA) in Q2 2022, closing a stake of 10,645 shares — an estimated $2K sold.

Tower Research Capital (TRC) first reported a position in ALNA in Q4 2017 and held it in 11 quarters. The position peaked at $27K in Q3 2020. 25 funds tracked by Wall St. Rank hold ALNA as of Q2 2022.

  • Tower Research Capital (TRC) reported no remaining Allena Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 10,645 Allena Pharmaceuticals shares in Q2 2022, an estimated $2K.
  • Tower Research Capital (TRC) first reported a position in Allena Pharmaceuticals in Q4 2017 and held it in 11 quarters.
  • Tower Research Capital (TRC)'s Allena Pharmaceuticals position peaked at $27K in Q3 2020.
  • 25 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q2 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2022, filed 15 Aug 2022.